<DOC>
	<DOCNO>NCT01775358</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability single dose ALRN-5281 administer subcutaneous injection healthy adult volunteer .</brief_summary>
	<brief_title>Phase 1 Safety Study ALRN-5281 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>1 . Healthy male female subject age 20 50 year , inclusive , time informed consent . 2 . Subjects must good health determine Investigator base detailed medical history , physical examination , vital sign , clinical laboratory test , ECGs screen evaluation . 3 . Ability provide write informed consent comply study requirement restriction . 4 . Is nonsmoker nontobacco user minimum 6 month prior screen 1 . History current evidence clinically significant cardiac , endocrinologic , hematologic , hepatobiliary , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator 2 . Previous treatment GH Releasing Hormone ( GHRH ) analog . 3 . Participation another clinical trial treatment investigational agent within 30 day 5 halflives , whichever longer , prior enrollment . 4 . History cancer within past five year ( exclude nonmelanoma skin cancer ) . 5 . History alcohol drug abuse dependence within 12 month screen determined Investigator . 6 . Subjects body weight &gt; 120 kg .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>